Physician profile
Darsit Shah
NPI 1083718456
$4,359.58
in general payments reported to CMS, 2019-2025
33 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Otology & Neurotology provider received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $194 · 2021: $298 · 2022: $485 · 2023: $952 · 2024: $882 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456 · Consulting Fee: $27.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.79 |
| Consulting Fee | $27.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $923.95 | 2019-2025 | Dupixent |
| Genzyme Corporation | $561.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $522.36 | 2019-2025 | Nucala |
| Aerin Medical INC. | $345.79 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.11 | 2021-2025 | Hyqvia, Eohilia, Takhzyro |
| Alk-Abello, INC | $262.63 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Optinose US, INC. | $240.13 | 2019-2025 | |
| Acclarent, INC | $126.87 | 2019 | |
| Stryker Corporation | $118.83 | 2019-2022 | |
| Kaleo, INC. | $118.78 | 2019-2024 | Auvi-Q |
| Csl Behring | $116.93 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Octapharma USA, INC. | $116.56 | 2019-2024 | Cutaquig |
| Bio Products Laboratory USA, INC. | $102.25 | 2019-2022 | |
| Shire North American Group INC | $56.08 | 2019 | |
| Hikma Pharmaceuticals USA | $50.50 | 2024 | Ryaltris |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $40.58 | 2019 | |
| Inspire Medical Systems, INC. | $39.98 | 2024 | Inspire |
| Axogen | $36.37 | 2019 | |
| Pfizer INC. | $28.06 | 2021-2024 | |
| Adma Biomanufacturing LLC | $27.65 | 2025 | |
| Davol INC. | $26.87 | 2019 | |
| Precigen, INC. | $20.18 | 2025 | |
| Genentech USA, INC. | $18.50 | 2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $18.08 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $17.58 | 2024 | Orladeyo |
| Merck Sharp & Dohme LLC | $16.96 | 2023 | |
| Incyte Corporation | $16.39 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.33 | 2021 | |
| Leo Pharma INC. | $14.87 | 2022 | |
| Ionis Pharmaceuticals, INC. | $14.48 | 2025 | |
| Aimmune Therapeutics, INC. | $14.24 | 2021 | |
| Cook Medical LLC | $14.08 | 2019 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darsit Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.